SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

APRE

Aprea Therapeutics, Inc.
NASDAQHealth Care

Latest close: 0.58 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◆Adverse 8-K filing●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Aug 28, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Aug 12, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
  3. Aug 12, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record41315 flagged findings
Reported transactions (Form 4)80since Mar 13, 2024 · and 1 other holding
Corporate events (8-K)30since May 17, 2022

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

Listing notice in force

The exchange has notified the company that it fails a continued-listing requirement (8-K, item 3.01 of Jul 23, 2026).

Deadline: Jan 19, 2027

  • minimum bid price · Nasdaq, rule 5550(a)(2) · notice of Jan 23, 2026 · extension granted · deadline Jan 19, 2027 (extension per the text)

The other times

Of the 30 issuers that received this notice 1 to 2 years ago, within the following 365 days 16 regained compliance, 23 did a reverse split and 1 filed a Form 25 (delisting). An issuer can be in more than one group.

Measured on our own SEC documents: the cohort is the issuers whose notices we read, not the whole market. Historical distribution, not a prediction.

Open the 8-K at the SEC

Reverse splits in 5 years

1 reverse split in 5 years (1:20 on Feb 13, 2023) · 1:20 cumulative

The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 413)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Aug 28, 268-K ↗Current report · Other events
  • Aug 13, 26SCHEDULE 13G/A ↗Passive stake · LYTTON LAURENCE W · 3.2% · event on Jun 30, 26 · amendment
  • Aug 12, 2610-Q ↗Quarterly report
  • Aug 12, 268-K ↗Current report · Results · Other events
  • Jul 23, 268-K ↗Current report · Listing notice (8-K 3.01)
  • Insider transaction · 8 Form 4 filingsshow all 8hide
  • Jun 17, 268-K ↗Current report · Shareholder vote results
  • May 15, 26424B7 ↗Securities offering
  • May 15, 26SCHEDULE 13G ↗Passive stake · Vestal Point Capital, LP · 9.9% · event on Mar 31, 26
  • May 13, 2610-Q ↗Quarterly report
  • May 13, 268-K ↗Current report · Results · Other events
  • Apr 30, 26DEFA14A ↗Shareholder meeting and votes
  • Apr 30, 26DEF 14A ↗Shareholder meeting and votes
  • Apr 29, 26424B3 ↗Securities offering
  • Apr 27, 26SCHEDULE 13G/A ↗Passive stake · Orin Hirschman · 9.9% · event on Mar 31, 26 · amendment
  • Apr 27, 26CORRESP ↗Correspondence with the SEC
  • Apr 27, 26UPLOAD ↗Correspondence with the SEC
  • Apr 22, 26S-3 ↗Securities offering

413 filings on record, the oldest from Aug 8, 19.

Listing the 25 most recent filings of the 413 on record.

8-Ks, explained

Stress10Structure15Governance11
  • Jul 23, 26StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Mar 30, 26StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
  • Jan 29, 26StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
  • Jan 23, 26StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Dec 9, 25StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Mar 25, 25GovernanceA senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
  • Structure3 material agreements entered2024show all 3hide
    • Nov 8, 24StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
    • Mar 12, 24StructureEntered a material agreement+5 more in the same filing8-K 1.01 ↗
    • Jan 26, 24StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Aug 24, 23GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Jul 5, 23StressListing notice (8-K 3.01)8-K 3.01 ↗
  • May 8, 23GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Apr 18, 23GovernanceAuditor change filing (8-K Item 4.01)+1 more in the same filing8-K 4.01 ↗
  • Feb 24, 23StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗

7 older filings not shown · The record reaches back to Dec 16, 19.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Nov 16, 22StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Sep 16, 22StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Aug 19, 22StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Jul 29, 22StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Jul 1, 22StressListing notice (8-K 3.01)8-K 3.01 ↗
  • May 17, 22StressListing notice (8-K 3.01)+7 more in the same filing8-K 3.01 ↗
  • Sep 18, 20StressListing notice (8-K 3.01)+3 more in the same filing8-K 3.01 ↗

The full record holds 10 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Soleus Private Equity Fund III, L.P.10.0%Apr 1, 26SCHEDULE 13G ↗9 co-filers on this document — the figure is the largest single stake, not their sum.
  • Orin Hirschman9.9%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
  • Vestal Point Capital, LP9.9%Mar 31, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • Squadron Master Fund LP9.9%Mar 30, 26SCHEDULE 13G ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Nantahala Capital Management, LLC4.5%Dec 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
show 3 more holdershide
  • Stonepine Capital Management, LLC4.3%Mar 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • LYTTON LAURENCE W3.2%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
  • Sio Capital Management, LLC1.9%Sep 30, 25SCHEDULE 13G/A ↗3 earlier filings

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Jan 30, 26Buy$5KJohn P. HamillSrVP/CFO/Prin Fin & Acct Ofcr↗
  • Jan 30, 26Buy$25KOren GiladPresident/CEO↗
  • Dec 10, 25Buy$6KJohn P. HamillSrVP/CFO/Prin Fin & Acct Ofcr↗
  • Dec 10, 25Buy$25KMarc Duey↗
  • Apr 3, 25Buy$6KOren GiladPresident/CEO↗
  • Apr 3, 25Buy$4KOren GiladPresident/CEO↗
  • Oct 23, 24Buy$2KOren GiladPresident/CEO↗
  • Oct 18, 24Sell$30KMarc Duey↗
  • Oct 16, 24Buy$132KMarc Duey↗
  • Oct 15, 24Buy$725Oren GiladPresident/CEO↗
  • Oct 14, 24Buy$3KOren GiladPresident/CEO↗
  • Oct 14, 24Buy$490Marc Duey↗

There are 4 more transactions in this stretch.

Stock compensation, tax and giftsshow the 24 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Jun 16, 26Compensationamount n/aBernd R. Seizinger↗
  • Jun 16, 26Compensationamount n/aRifat Pamukcu↗
  • Jun 16, 26Compensationamount n/aMarc Duey↗
  • Jun 16, 26Compensationamount n/aJEAN-PIERRE BIZZARI↗
  • Jun 16, 26Compensationamount n/aJOHN B HENNEMAN III↗
  • Jun 16, 26Compensationamount n/aRichard Peters↗
  • Jun 16, 26Compensationamount n/aGabriela Gruia↗
  • Jun 16, 26Compensationamount n/aMichael Grissinger↗
  • Mar 12, 26Compensationamount n/aJohn P. HamillSrVP/CFO/Prin Fin & Acct Ofcr↗
  • Mar 12, 26Compensationamount n/aOren GiladPresident/CEO↗
  • Jun 5, 25Compensationamount n/aJEAN-PIERRE BIZZARI↗
  • Jun 5, 25Compensationamount n/aMarc Duey↗
  • Jun 5, 25Compensationamount n/aMichael Grissinger↗
  • Jun 5, 25Compensationamount n/aGabriela Gruia↗
  • Jun 5, 25Compensationamount n/aJOHN B HENNEMAN III↗
  • Jun 5, 25Compensationamount n/aRifat Pamukcu↗
  • Jun 5, 25Compensationamount n/aRichard Peters↗
  • Jun 5, 25Compensationamount n/aBernd R. Seizinger↗
  • Mar 27, 25Compensationamount n/aOren GiladPresident/CEO↗
  • Mar 27, 25Compensationamount n/aJohn P. HamillSrVP/CFO/Prin Fin & Acct Ofcr↗
  • Jun 20, 24Compensationamount n/aMarc Duey↗
  • Jun 20, 24Compensationamount n/aMichael Grissinger↗
  • Jun 20, 24Compensationamount n/aJOHN B HENNEMAN III↗
  • Jun 20, 24Compensationamount n/aRichard Peters↗

The full record holds 65 transactions and goes back to Aug 23, 22.

Its sector and its market

Aprea Therapeutics, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Aprea Therapeutics, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Aprea Therapeutics, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
413 documents on file, from Aug 8, 2019 to Aug 28, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.